CT lung cancer screening could save up to 12,000 lives per year in the United States - and even more could be saved if the criteria were expanded.
CT lung cancer screening could save up to 12,000 lives per year in the United States, says one study published in the most recent issue of Cancer. However, a second recent study in the New England Journal of Medicine found that even more lives could be saved if screening selection criteria were expanded to cover a broader group of people.
Results from the National Lung Screening Trial (NLST) published in 2011 showed that low-dose CT screening among people at high risk for lung cancer reduced cancer mortality by 20 percent compared with chest X-ray alone. High-risk candidates for screening include current or former smokers with no signs and symptoms or history of lung cancer, with a smoking history of at least 30 pack-years.
For the first study, researchers from the American Cancer Society used the NLST findings to estimate the number of lives that could be saved annually if the screening guidelines were implemented among all eligible Americans. Analyses were performed by age, sex, and smoking status.
Using census data, the researchers identified about 8.6 million Americans (5.2 million men, 3.4 million women) who were eligible for lung cancer screening in 2010. If 100 percent of the group had been screened and based on the 20 percent drop in deaths found in the NLST trial, the researchers estimated that 12,250 lung cancer deaths could have been prevented (8,990 men, 3,260 women).
Because 100 percent participation is not realistic, the researchers recalculated the numbers based on a 70 percent participation rate, which resulted in 8,575 lives saved.
In a second study, from Brock University in Ontario, Canada, researchers concluded that if lung cancer screening guidelines were expanded to include those from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PCLO), even more lives would be saved.
The PCLO criteria include body mass index, level of education, family history of lung cancer, and presence of chronic obstructive pulmonary disease (COPD), in addition to smoking history and age.
Using this approach, which the researchers called PLCOM2012, allowed for using a broader history, rather than the NLST criteria yes/no questions and answers. Applying the PLCO model, the researchers found that among 37,332 smokers, 81 more patients were screened and were diagnosed with lung cancer than would have been with the NLST model.
Sensitivity rose from 71 percent to 83 percent when the PCLO criteria were used. “The use of the PLCOM2012 model was more sensitive than the NLST criteria for lung-cancer detection,” concluded the study’s authors.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.